Sepracor, Inc.

A K Gunnar Aberg

Raymond L Woosley

John R McCullough

James W Young

Emil R Smith

Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.

Compositions of descarboethoxyloratadine

Methods for the treatment of allergic rhinitis

Methods for treating urticaria using descarboethoxyloratadine

Methods and compositions are disclosed utilizing the optically pure (S)-isomer of lomefloxacin to treat bacterial infection. In particular, this compound is a potent drug for the treatment of Mycobacteria infection.

Methods and compositions for treating infection using optically pure (S)-lomefloxacin

Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

Methods for treating disorders using norastemizole in combination with other active ingredients

Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients

Compositions are disclosed utilizing the optically pure (&minus;) isomer of norcisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease, emesis, dyspepsia and other conditions while substantially reducing the concomitant liability of adverse effects associated with cisapride. The (&minus;) isomer of norcisapride also avoids the adverse drug interactions associated with racemic cisapride and other therapeutic agents.

Compositions of optically pure (&minus;) norcisapride

Compositions for treating infection using optically pure (S)-lomefloxacin

Methods and compositions for treating allergic disorders and other disorders using norastemizole in combination with other active ingredients

Methods for treating allergic disorders and other disorders using norastemizole

Growing community of inventors

Westborough, MA, United States of America

A K Gunnar Aberg